JP6721606B2 - シェーグレン症候群の治療にける使用のための特定のトリフルオロエチルキノリン類似体 - Google Patents

シェーグレン症候群の治療にける使用のための特定のトリフルオロエチルキノリン類似体 Download PDF

Info

Publication number
JP6721606B2
JP6721606B2 JP2017554426A JP2017554426A JP6721606B2 JP 6721606 B2 JP6721606 B2 JP 6721606B2 JP 2017554426 A JP2017554426 A JP 2017554426A JP 2017554426 A JP2017554426 A JP 2017554426A JP 6721606 B2 JP6721606 B2 JP 6721606B2
Authority
JP
Japan
Prior art keywords
syndrome
sjogren
treatment
mice
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017554426A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018513862A5 (enExample
JP2018513862A (ja
Inventor
アンソニー アレン、ロジャー
アンソニー アレン、ロジャー
バロン、フランチェスカ
アンソニー ファーイ、ウィリアム
アンソニー ファーイ、ウィリアム
ナヤール、サバ
Original Assignee
ユーシービー バイオファルマ エスアールエル
ユーシービー バイオファルマ エスアールエル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユーシービー バイオファルマ エスアールエル, ユーシービー バイオファルマ エスアールエル filed Critical ユーシービー バイオファルマ エスアールエル
Publication of JP2018513862A publication Critical patent/JP2018513862A/ja
Publication of JP2018513862A5 publication Critical patent/JP2018513862A5/ja
Application granted granted Critical
Publication of JP6721606B2 publication Critical patent/JP6721606B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2017554426A 2015-04-21 2016-04-20 シェーグレン症候群の治療にける使用のための特定のトリフルオロエチルキノリン類似体 Active JP6721606B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1506786.1A GB201506786D0 (en) 2015-04-21 2015-04-21 Therapeutic use
GB1506786.1 2015-04-21
PCT/EP2016/058810 WO2016170014A1 (en) 2015-04-21 2016-04-20 A specific trifluoroethyl quinoline analogue for use in the treatment of sjögren's syndrome

Publications (3)

Publication Number Publication Date
JP2018513862A JP2018513862A (ja) 2018-05-31
JP2018513862A5 JP2018513862A5 (enExample) 2019-04-25
JP6721606B2 true JP6721606B2 (ja) 2020-07-15

Family

ID=53298950

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017554426A Active JP6721606B2 (ja) 2015-04-21 2016-04-20 シェーグレン症候群の治療にける使用のための特定のトリフルオロエチルキノリン類似体

Country Status (27)

Country Link
US (1) US10493074B2 (enExample)
EP (1) EP3285772B1 (enExample)
JP (1) JP6721606B2 (enExample)
KR (1) KR102627370B1 (enExample)
CN (1) CN107530344B (enExample)
AR (1) AR105552A1 (enExample)
AU (1) AU2016251236B2 (enExample)
BR (1) BR112017020591B8 (enExample)
CA (1) CA2981631C (enExample)
CL (1) CL2017002669A1 (enExample)
CO (1) CO2017010573A2 (enExample)
CY (1) CY1122572T1 (enExample)
DK (1) DK3285772T3 (enExample)
EA (1) EA032432B1 (enExample)
ES (1) ES2763335T3 (enExample)
GB (1) GB201506786D0 (enExample)
HR (1) HRP20192273T1 (enExample)
HU (1) HUE047162T2 (enExample)
IL (1) IL254766B (enExample)
LT (1) LT3285772T (enExample)
MX (1) MX2017013148A (enExample)
MY (1) MY192972A (enExample)
PL (1) PL3285772T3 (enExample)
PT (1) PT3285772T (enExample)
SG (1) SG11201707789YA (enExample)
SI (1) SI3285772T1 (enExample)
WO (1) WO2016170014A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
GB201708856D0 (en) 2017-06-02 2017-07-19 Ucb Biopharma Sprl Seletalisib crystalline forms

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2612862T (lt) * 2004-05-13 2017-01-25 Icos Corporation Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės delta inhibitoriai
HRP20160350T1 (hr) * 2007-03-23 2016-05-06 Amgen Inc. Heterociklički spojevi i njihove uporabe
LT2496567T (lt) * 2009-11-05 2017-11-27 Rhizen Pharmaceuticals S.A. Nauji benzopirano kinazės moduliatoriai
UA112517C2 (uk) * 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
AR082799A1 (es) * 2010-09-08 2013-01-09 Ucb Pharma Sa Derivados de quinolina y quinoxalina como inhibidores de quinasa
ES2667173T3 (es) * 2013-06-14 2018-05-09 Gilead Calistoga Llc Inhibidores de fosfatidilinositol 3-quinasa

Also Published As

Publication number Publication date
IL254766B (en) 2020-05-31
AU2016251236A1 (en) 2017-11-09
EA032432B1 (ru) 2019-05-31
CY1122572T1 (el) 2021-01-27
CA2981631C (en) 2023-02-21
ES2763335T3 (es) 2020-05-28
SG11201707789YA (en) 2017-11-29
EA201792318A1 (ru) 2018-05-31
HRP20192273T1 (hr) 2020-03-06
US10493074B2 (en) 2019-12-03
EP3285772B1 (en) 2019-10-02
KR102627370B1 (ko) 2024-01-18
PL3285772T3 (pl) 2020-05-18
BR112017020591B8 (pt) 2023-05-16
LT3285772T (lt) 2020-01-10
CO2017010573A2 (es) 2018-03-09
KR20170140245A (ko) 2017-12-20
SI3285772T1 (sl) 2020-02-28
HUE047162T2 (hu) 2020-04-28
EP3285772A1 (en) 2018-02-28
AU2016251236B2 (en) 2018-06-14
IL254766A0 (en) 2017-12-31
CN107530344B (zh) 2020-03-17
MX2017013148A (es) 2018-02-21
CL2017002669A1 (es) 2018-05-11
GB201506786D0 (en) 2015-06-03
WO2016170014A1 (en) 2016-10-27
BR112017020591A2 (pt) 2018-07-03
PT3285772T (pt) 2020-01-14
US20180092921A1 (en) 2018-04-05
CN107530344A (zh) 2018-01-02
MY192972A (en) 2022-09-20
BR112017020591B1 (pt) 2023-02-07
JP2018513862A (ja) 2018-05-31
CA2981631A1 (en) 2016-10-27
AR105552A1 (es) 2017-10-18
DK3285772T3 (da) 2020-01-13

Similar Documents

Publication Publication Date Title
AU2014249456B2 (en) Use of levocetirizine and montelukast in the treatment of autoimmune disorders
Chen et al. Reduced hepatotoxicity by total glucosides of paeony in combination treatment with leflunomide and methotrexate for patients with active rheumatoid arthritis
JP6837486B2 (ja) 加齢に関連する認知障害及び神経炎症を予防及び／又は治療する方法
ES2940239T3 (es) Tratamiento de enfermedades autoinmunitarias con combinaciones de agonistas de RXR y hormonas tiroideas
JP2019511495A (ja) ＧＳＫ３β阻害薬チデグルシブによるＣＤＫＬ５障害の治療
TWI794885B (zh) 全身紅斑性狼瘡之治療
EP2813224A1 (en) Prophylactic or therapeutic agent for idiopathic inflammatory myopathies
US20250082688A1 (en) Compositions and methods for williams syndrome (ws) therapy
Agarwal et al. Subcutaneous repository corticotropin gel for non-infectious panuveitis: reappraisal of an old pharmacologic agent
Napolitano et al. Probiotic supplementation improved acute anterior uveitis of 3-year duration: a case report
Wang et al. KGF-2 alleviates dry eye disease by regulating the HMGB1/TLR4 pathway
KR102627370B1 (ko) 쇼그렌 증후군의 치료에 사용하기 위한 특정 트리플루오로에틸 퀴놀린 유사체
Russell et al. Analgesics, opioids, and NSAIDs
WO2015160249A2 (en) Use of enoximone in the treatment of atopic immune-related disorders, in pharmaceutical composition as well as in pharmaceutical preparation
CN101940789A (zh) 糖皮质激素在制备迟发性出血性膀胱炎治疗药物中的应用
AU2021360501A1 (en) Method of preventing kidney injury disruption of intestinal lymphatics
JP2026049047A (ja) 変形性膝関節症および肩関節周囲炎の疼痛改善剤
Kolb et al. Effective Use of Tociluzimab, an Anti-Interleukin 6 Agent for the Treatment of Steroid-Refractory Grade IV Intestinal Acute Graft-Versus-Host Disease in a Child with Sickle Cell Disease
Moccia et al. Review of oral psoriasis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190315

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190315

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200501

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200526

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200618

R150 Certificate of patent or registration of utility model

Ref document number: 6721606

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250